Article: Ampligen trial of CFS patients in Belgium shows significant improvements.

SAN FRANCISCO--(HealthWire)--Oct. 15, 1996--

No evidence of significant toxicities

Results of a Belgium clinical study presented today at the annual scientific meeting of the American Association for Chronic Fatigue Syndrome (AACFS) evidenced that the antiviral and immune modulatory drug Ampligen(R) produced significant physical and cognitive improvements among patients suffering from Chronic Fatigue Syndrome. The study was presented by Kenny De Meirleir, M.D., Ph.D. from the University of Brussels, and by David Strayer, M.D., Professor of Medicine at Allegheny University, PA, and Medical Director for HEMISPHERx.

The ...

Related newspaper, magazine, and journal articles:

 
 
Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!